PABAL RTS

is indicated for the prevention of postpartum haemorrhage due to uterine atonia.

Carbetocin is intended to be used only in well-equipped specialized obstetric rooms with a qualified, experienced and permanently available staff.

The use of carbetocin before delivery (regardless of the phase), is not appropriate, because its uterotonic activity persists for several hours.

This effect differs from that of oxytocin whose activity decreases very rapidly after the infusion stop.

If the vaginal or uterine bleeding persists after the administration of carbetocin, the cause should be sought.

Placental residues, perineal, vaginal and cervical lesions, inadequate repair of the uterus or disorder of blood coagulation will be more particularly sought.

If the laboratory is not able to perform an active activity in a laboratory, the laboratory is not capable of performing an active activity in a laboratory, or in an laboratory, or in a laboratory, or in a laboratory, or in a laboratory, or in a laboratory, or in a laboratory, or in a laboratory, or in a laboratory, the laboratory is not capable of performing an active activity in a laboratory, or in a laboratory, or laboratory, or in a laboratory, or laboratory, or laboratory, or laboratory, or laboratory, or laboratory, or laboratory, or laboratory.

The pharmacotherapeutic group: ocytocin and analogues, ATC code: H01BB03 Mechanism of action Carbetocin has the same pharmacological and clinical properties as a long-acting oxytocin agonist.

Carbetocin, like oxytocin, binds selectively to the uterine smooth muscle oxytocin receptors.

It stimulates regular contractions of the uterus, increases the frequency of contractions already present and the tone of the uterine muscle.

On the uterus in postpartum phase, carbetocin increases the frequency and power of spontaneous uterine contractions.

The constrictive activity of the carbetocin in the uterus is rapidly initiated by the laboratory, with a total of two minutes of the procedure.

In clinical trials with carbetocin, the adverse events were of the same nature and frequency as those observed with oxytocin.Intravenous*.

• Summary Table of Adverse Reactions System Classification of Organs Very Common ≥1/10 Common ≥1/100 and <1/10 Not known (cannot be estimated from available data) Blood and lymphatic disorders Anemia Nervous system disorders Headache, tremors Sensation of dizziness Vascular disorders Hypotension, flushing Respiratory, thoracic and mediastinal disorders Thoracic, dyspnoea Gastrointestinal disorders Nausea, abdominal pains Metallic taste, vomiting Skin and subcutaneous tissue disorders Pruritus musculoskeletal and systemic disorders Absorbent disorders Tabic disorders Tabic and systemic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders Tabic disorders.